"
According to the latest report published by Data Bridge Market Research, the Daratumumab Market
CAGR Value
As per Data Bridge Market Research analysis, the daratumumab market was valued at USD 12.86 billion in 2025 and is projected to reach USD 19.29 billion by 2033, growing at a CAGR of 5.20% from 2026 to 2033
An influential Daratumumab Market advertising report puts light on the types of customers, product-buyer insights, market changes over last few years, reactions of various geographic regions, new developments in the market, actions of other corporate players and more. This marketing analysis gives an examination of various segments that are relied upon to witness the quickest development amid the estimate forecast frame. All the statistics are signified in graphical and tabular format for a clear understanding on facts and figures. By accomplishing an inspiration from the marketing strategies of rivals, businesses can set up inventive ideas and striking sales targets which in turn make them achieve competitive advantage over its competitors.
Stay informed with our latest keyword market research covering strategies, innovations, and forecasts. Download full report: https://www.databridgemarketresearch.com/reports/global-daratumumab-market
Daratumumab Market Segmentation and Market Companies
Segments
- Indication: The daratumumab market can be segmented based on different indications for which the drug is used, such as multiple myeloma and other hematologic malignancies. Multiple myeloma is the primary indication for which daratumumab is prescribed, with significant market share in this segment due to its effectiveness in treating this disease.
- Dosage Form: Another segmentation factor is the dosage form of daratumumab, which includes injectable solutions for intravenous administration. The dosage form segment plays a crucial role in determining the ease of administration and patient compliance, thus impacting market growth.
- Distribution Channel: Distribution channels like hospitals, clinics, specialty pharmacies, and online pharmacies form another important segment of the daratumumab market. The accessibility and availability of the drug through various distribution channels influence its market penetration and reach.
Market Players
- Johnson & Johnson Services, Inc.: Johnson & Johnson is a key player in the global daratumumab market, offering the drug under the brand name Darzalex. The company's strong market presence, extensive R&D capabilities, and strategic partnerships contribute significantly to its market leadership.
- Genmab A/S: Genmab A/S is a prominent player in the daratumumab market, as the company co-developed the drug with Janssen Biotech, Inc. Genmab's expertise in antibody technology and collaboration with Janssen enhance its position in the market.
- Amgen Inc.: Amgen Inc. is another significant market player in the daratumumab segment, marketing the drug under the brand name Kyprolis. The company's focus on innovation, product development, and global distribution network strengthens its competitive edge in the market.
- Bristol Myers Squibb: Bristol Myers Squibb, through its acquisition of Celgene Corporation, holds a strategic position in the daratumumab market. The company's diversified portfolio, strong pipeline of oncology drugs, and robust marketing strategies contribute to its market presence.
The global daratumumab market showcases steady growth and intense competition among key players vying for market share. Factors such as increasing prevalence of multiple myeloma, growing demand for innovative treatments, and ongoing research and development initiatives drive market expansion. The segmentation based on indication, dosage form, and distribution channel provides insights into the diverse dynamics shaping the market landscape. Collaboration, strategic alliances, and product launches are key strategies adopted by market players to strengthen their market position and cater to evolving patient needs.
The global daratumumab market is poised for continued growth and evolution, driven by various factors that shape its landscape. One key trend that stands out is the increasing focus on personalized medicine and targeted therapies in oncology, including the treatment of multiple myeloma and other hematologic malignancies. As healthcare providers and pharmaceutical companies strive to enhance patient outcomes and minimize adverse effects, the demand for innovative and effective treatments like daratumumab is expected to rise.
Moreover, the competitive dynamics within the daratumumab market are intensifying, with key players leveraging their strengths in R&D, marketing, and distribution to gain a competitive edge. Johnson & Johnson Services, Inc. leads the market with its well-established brand Darzalex, supported by a robust market presence and strategic partnerships. Genmab A/S, in collaboration with Janssen Biotech, Inc., capitalizes on its antibody technology expertise to enhance its market position. Amgen Inc., known for its innovation and global reach, markets daratumumab under the brand name Kyprolis, further fueling market competition. Bristol Myers Squibb, following its acquisition of Celgene Corporation, strengthens its market foothold through a diversified portfolio and strategic marketing initiatives.
Furthermore, as the daratumumab market continues to expand, the segmentation based on indications, dosage forms, and distribution channels offers valuable insights into consumer preferences and market trends. The indication segment, led by multiple myeloma, remains a significant driver of market growth due to the drug's efficacy in treating this condition. The dosage form segment, focusing on injectable solutions for intravenous administration, plays a crucial role in patient compliance and treatment outcomes. The distribution channels, including hospitals, clinics, specialty pharmacies, and online platforms, contribute to the drug's accessibility and market reach, influencing overall market penetration.
In conclusion, the global daratumumab market presents a dynamic and competitive landscape characterized by innovation, collaboration, and strategic market positioning. With a focus on personalized medicine, targeted therapies, and patient-centric care, market players are poised to capitalize on emerging opportunities and meet the evolving needs of patients with hematologic malignancies. As research and development initiatives continue to drive advancements in oncology treatments, the daratumumab market is expected to witness sustained growth and evolution, with key players striving to maintain their competitive advantage in this dynamic healthcare landscape.The daratumumab market, characterized by its segmentation based on indications, dosage forms, and distribution channels, presents a variety of dynamics that shape its competitive landscape. The indication segment, with a focus on multiple myeloma as the primary driver, underscores the drug's efficacy in treating this condition, leading to significant market share within this segment. The emphasis on personalized medicine and targeted therapies in oncology is a key trend driving the demand for innovative treatments like daratumumab, especially in the treatment of hematologic malignancies. This trend aligns with the increasing prevalence of multiple myeloma and the growing need for effective and well-tolerated therapies in this space.
In terms of dosage forms, the availability of daratumumab in injectable solutions for intravenous administration plays a crucial role in patient compliance and treatment outcomes. The ease of administration and patient convenience associated with the dosage form segment contribute to the overall market growth by ensuring a favorable patient experience and treatment adherence. Furthermore, the distribution channels encompassing hospitals, clinics, specialty pharmacies, and online platforms provide varied access points for patients to obtain daratumumab, ultimately influencing market penetration and reach. The accessibility and availability of the drug through diverse distribution channels contribute to its market expansion and cater to the needs of patients across different healthcare settings.
The competitive dynamics within the daratumumab market are driven by key players' strategic initiatives in R&D, marketing, and distribution. Johnson & Johnson Services, Inc., Genmab A/S, Amgen Inc., and Bristol Myers Squibb are prominent market players leveraging their strengths to gain a competitive edge in the market. These companies' emphasis on collaboration, strategic alliances, and product launches underscores their commitment to strengthening market positions and addressing evolving patient needs. With a focus on innovation, market players are aligning their efforts towards enhancing patient outcomes, driving research and development in oncology treatments, and ensuring a patient-centric approach in the competitive daratumumab market.
In conclusion, the global daratumumab market presents a dynamic landscape shaped by evolving trends in personalized medicine, targeted therapies, and market segmentation based on indications, dosage forms, and distribution channels. As market players continue to navigate this competitive space, collaboration, innovation, and strategic positioning will be crucial in maintaining market leadership and meeting the evolving needs of patients with hematologic malignancies. The market's growth trajectory is further supported by the increasing demand for effective treatments, the emphasis on patient-centric care, and the ongoing advancements in oncology research and development, signaling a promising outlook for the daratumumab market's continued evolution and expansion.
Frequently Asked Questions About This Report
How is the Daratumumab Market segmented by end-use industry?
What was the valuation of the application segment in 2025?
What are the key product innovations launched in the Daratumumab Market in 2025?
How much revenue did the ground/minced products segment generate in 2025?
How does Fear of Missing Out (FOMO) drive Daratumumab Market tech adoption?
How are Green regulations changing the Daratumumab Market?
What is the influence of social media on Daratumumab Market demand?
How will the Daratumumab Market contribute to the global [Goal, e.g., Net Zero]?
What are the insurance requirements for the Daratumumab Market industry?
What are the key players in the Daratumumab Market for consumer goods?
What is the impact of the current global scenario on the Daratumumab Market 2040?
How are manufacturers reducing their carbon footprint in the Daratumumab Market?
How is vendor selection criteria changing in the Daratumumab Market?
How does the Daratumumab Market size in India compare to the U.S.?
Browse More Reports:
Global Probiotics in Ruminants Market
Global Aromatherapy Diffusers Market
Global Stainless Steel Foil Market
Global Financial Audit Professional Services Market
Global Genetic Disorders Market
Global Pallet Wrap Market
Global Platform Based Master Card Market
Global Aerosol Paints Market
Global Acidifiers Market
Global Bortezomib Market
Global Hospital Staffing Market
Global Cloud Migration Market
Global Creatinine Measurement Market
Global mRNA Therapeutics Market
Global Hydrodesulfurization Catalysts Market
Contact Us:
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC : +653 1251 976
Email:- [email protected]"
Comments